糖肾康对DN模型大鼠血清MCP-1和ICAM-1水平的影响  

The Effect of Tangshenkang on MCP-1 and ICAM-1 Levels in the Serum of DN Rat Models

作　　者：胡顺金[1] 吴幽婉 杨丽 王东[1] 高磊 金华[1] 曹媛茹 王亿平[1] 

机构地区：[1]安徽中医药大学第一附属医院,安徽合肥230031 [2]安徽中医药大学研究生院,安徽合肥230038

出　　处：《陕西中医药大学学报》2018年第1期83-87,共5页Journal of Shaanxi University of Chinese Medicine

基　　金：安徽省高校省级科学研究项目(2013z172);安徽省卫生厅中医药科研项目(2012zy12)

摘　　要：目的 :观察糖肾康对糖尿病肾病(DN)大鼠血清中单核细胞趋化性蛋白-1(monocytechemotaticprotein-1,MCP-1)、细胞间粘附分子-1(intercellularcelladhesionmolecule-1,ICAM-1)的影响,探讨糖肾康防治DN模型大鼠的作用机制。方法将40只SD大鼠随机分为正常组(n=8)和造模组(n=32)。以三联法(手术+高糖高脂饮食+链脲佐菌素)诱导产生DN大鼠模型,造模过程中死亡5只,余下27只模型大鼠随机分为模型组(n=9)、贝那普利组(n=9)和糖肾康组(n=9)。糖肾康组按0.8g/100g·d灌胃,贝那普利组按0.15mg/100g·d灌胃,正常组及模型组给予等量温水灌胃,连续灌胃给药8周。观察各组大鼠尿白蛋白/尿肌酐(ACR)、肾脏组织病理及血清MCP-1、ICAM-1水平变化。结果糖肾康可消减DN模型大鼠的ACR水平(P<0.01),改善肾脏病理形态损害。模型组、贝那普利组和糖肾康组血清MCP-1、ICAM-1水平均高于正常组(P<0.01);与模型组比较,治疗后贝那普利组与糖肾康组血清MCP-1、ICAM-1水平明显降低(P<0.01),糖肾康组和贝那普利组比较无显著性差异(P>0.05)。结论糖肾康可有效减少DN模型大鼠尿蛋白,减轻肾脏病理形态损害,其机制可能与降低血清MCP-1、ICAM-1水平,抑制肾脏免疫炎症反应有关。Objective： To observe the effect of Tangshenkang on MCP-1 and ICAM-1 levels in the serum of DN rat models,and study its prevention and treatment mechanism. Method： 40 SD rats were randomly divided into normal group（ n = 8） and model group（ n = 32）. DN rat models were induced by triple therapy（ operation ＋ high-glucose and high-fat diet ＋ streptozotocin）. Five rats died during the modeling,and the remaining 27 rats were randomly dividedinto model group（ n = 9） Benazepril group（ n = 9） and Tangshenkang group（ n = 9）. The rats in Tangshenkang group were given gavage at a dosage of 0. 8 g/100 g · d,the benazepril group was gavaged at 0. 15 mg/100 g · d,the rats in the normal group and the model group were given the same amount of warm water for gavage,all for 8 weeks. Urinary albumin/urinary creatinine（ ACR）,renal histopathology and changes of serum levels of MCP-1 and ICAM-1 in rats were observed. Result： Tangshenkang can reduce the ACR level in DN rat models（ P〈0. 01）,and improve renal pathological damage. The levels of serum MCP-1 and ICAM-1 in model group,benazepril group and Tangshenkang group were higher than those in normal group（ P〈0. 01）. Compared with model group,Serum levels of MCP-1 and ICAM-1 in Tangshenkang group and Benazepril group were significantly decreased（ P〈0. 01）,but there was no significant difference between the two groups（ P〈0. 05）. Conclusion： Tangshenkang can effectively reduce urinary protein in DN rat models and reduce renal pathological damage,which may be related to the decrease of serum MCP-1,ICAM-1 levels and the inhibition of renal immune inflammation.

关 键 词：糖肾康 糖尿病肾病 单核细胞趋化性蛋白-1 细胞间粘附分子-1 

分 类 号：R285.5[医药卫生—中药学]